Respondents broadly supported clearer guidance on how evidence on health inequalities should be presented and how impacts are ...

Connecting 80+ EHS experts in pharma and biopharma on the West coast, this year's meeting will address the challenges of ...

For well over a decade, scientists, health leaders, and global organisations have sounded the alarm on antimicrobial ...

The deal for CARGO, which remains relatively well funded despite its troubles, comes with a contingent value right (CVR) that ...

Eli Lilly has won a green light from the FDA for new dosing for its Alzheimer's disease therapy Kisunla, which carries a ...

The acquisition – which will see MSD pay $107 for each American Depository Share (ADS) in UK-headquartered Verona – is the ...

The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...

Despite a certain amount of upheaval at the FDA, the agency has continued to keep up with its scheduled approvals and clearances. At BIO 2025, editor-in-chief Jonah Comstock sat down with Mursla Bio ...

So, what were the major themes to come out of BIO Boston 2025? Who’s getting excited about what? And – besides the obvious ...

Apogee is pitching APG777 as a 'best-in-class' IL-13 inhibitor that could offer robust efficacy and less-frequent dosing than ...

KalVista Pharma has finally received FDA approval for its oral kallikrein inhibitor sebetralstat, becoming the first ...

On the forefront of healthcare change, turning innovative science into value for patients: Astellas at ASCO 2025 At this year ...